0.00Open0.00Pre Close0 Volume0 Open Interest66.00Strike Price0.00Turnover183.28%IV-15.49%PremiumNov 29, 2024Expiry Date12.10Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9481Delta0.0127Gamma6.35Leverage Ratio-0.1979Theta0.0021Rho6.02Eff Leverage0.0049Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet